AUTHORS
Alexander P. Boardman, MD, Adhithi Rajagopalan, MD PhD2, Preet Kaur, PhD3, Sophia Chen, MD4, Katerina Su5, Ryan Lee6, Nathan Duong, BS7, Jennifer Angelica Funes, MS8, Brandon D Ng, Ph.D.9, Jacob S. Fischman10, Alyssa Massa11, Dylan Manuele12, Harold K. Elias, MD13, Andri Leo Leo Lemarquis, MD,PhD14, Sandeep Sunder Raj, MD15, Kimon Argyropoulos, MD, PhD16, Mohamed Atmane17, Ileana C Miranda, DVM18, Oscar Colunga Flores, MS19, Naomi Lee, DVM20, Colt Egelston, PhD21, Anastasia I. Kousa, PhD22, Marcel R.M. van den Brink Jr, M.D., Ph.D.23, Scott E. James, MD,PhD24
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 City of Hope National Medical Center, Duarte, California, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 City of Hope National Medical Center, Duarte, California, United States
20 City of Hope National Medical Center, Duarte, California, United States
21 City of Hope National Medical Center, Duarte, California, United States
22 City of Hope National Medical Center, Duarte, California, United States
23 City of Hope National Medical Center, Duarte, California, United States
24 City of Hope National Medical Center, Duarte, California, United States
ABSTRACT
CAR T cell toxicity remains a major limitation of therapy, restricting the range of safely targetable antigens. Differentiation and exhaustion limit T cell-mediated immunopathology, but how these programs can be harnessed to restrain CAR T cell toxicity while retaining efficacy remains a major challenge. We hypothesized that understanding the drivers of toxic CAR T cell activity could inform strategies to improve CAR T cell efficacy. To test this, we developed a syngeneic model of a CD24-directed CAR targeting an antigen broadly expressed on normal hematologic and nonhematologic tissues.
To determine whether toxicity in our model was dictated by intracellular signaling rather than antigen recognition, we first compared a conventional CD28ζ CAR with a single-ITAM mutant 1XX CAR, previously shown to limit differentiation and enhance antitumor activity. Across leukemia, lymphoma, and myeloma models, 1XX CAR T cells caused severe weight loss, serum cytokine elevation, and pulmonary toxicity, whereas CD28ζ CAR T cells caused only transient weight loss. To test if this toxicity was due to off-target activation of CAR T cells we used CD24-deficient recipient mice (CD24KO). In the absence of healthy tissue expression of CD24, 1XX CAR T cells eliminated leukemia and supported long-term survival without causing cytokine elevation or lethal toxicity. These findings established recognition of CD24 on healthy tissue as the essential driver of toxicity.
We next probed for intracellular programs that distinguish 1XX from CD28ζ CAR T cells to account for this difference. Human and murine transcriptomic analyses consistently identified enrichment of NFκB and IFNγ-response programs in toxic 1XX CAR T cells. Increased NFκB activity required CD28 signaling through the PYAP motif, identifying canonical NFκB as a proximal regulator of toxicity. Accordingly, engineered stabilization of IκBα reduced cytokine release, pulmonary accumulation, and lung pathology, but impaired tumor control against rapidly progressive leukemia. In a myeloma model with slower growth, CD28ζ and NFκB-inhibited 1XX CAR T cells achieved disease control and long-term survival, showing that NFκB modulation can maintain efficacy while reducing toxicity. Having established that attenuating NFκB can uncouple toxicity from efficacy, we next sought to understand the cellular states produced by this perturbation.
Single-cell transcriptomics of pre-infusion CAR T cell products demonstrated that NFκB-inhibition redirected 1XX CAR T cells toward differentiation and exhaustion programs resembling CD28ζ CAR T cells, whereas 1XX CAR T cells maintained an NFκB-high, IFNγ-responsive state. To determine how this IFNγ-response state relates to tissue toxicity, we performed single-nucleus sequencing lung tissues from recipients of CAR T cells. This analysis revealed increased IFNγ-response programs in macrophages and stress and repair programs across stromal and immune populations in recipients of 1XX CAR T cells. Lung-infiltrating 1XX CAR T cells subsequently upregulated cytotoxic differentiation and exhaustion signatures suggesting that inflammatory tissue cues reinforce these programs in vivo. Consistent with these results, post-infusion CD19-CAR T cell transcriptomes from lymphoma patients showed stronger IFNγ-response, differentiation, and exhaustion signatures in grade 2 versus grade 1 cytokine release syndrome.
Unexpectedly, IFNγ deficiency of 1XX CAR T cells exacerbated toxicity and strongly attenuated differentiation and exhaustion signatures. Factorial CAR T cell analysis of NFκB inhibition and IFNγ deficiency identified progressively greater cytotoxic differentiation and exhaustion from IFNγ-deficient, to NFκB-inhibited IFNγ-deficient, to wild-type, and finally to NFκB-inhibited wild-type CAR T cells. These results indicate that IFNγ functions not only as an inflammatory cytokine but also as a regulator that promotes adaptive differentiation.
These results define a circuit in which NFκB drives T cell cytokine production, tissue accumulation, and immunopathology, while simultaneously promoting IFNγ dependent differentiation that restrains toxicity. Disruption of IFNγ removes this regulatory checkpoint and exacerbates toxicity, challenging the view of IFNγ as solely a pathogenic driver of inflammation. This defines a therapeutic strategy to uncouple CAR T cell toxicity from efficacy and may enable safe targeting of a broader range of antigens with off-tumor expression.
DISCLOSURES
Alexander P. Boardman, MD: Incyte - Honoraria; Incyte - Research Funding; BMS - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony)